PDF herunterladen
Notfall Medizin 2003; 29(1/2): 32-41
DOI: 10.1055/s-2003-37794
Aktuelles Wissen

© Georg Thieme Verlag Stuttgart · New York

Neues zu Pathophysiologie und Therapie der Migräne

KopfschmerzenV. Limmroth1 , H.-C. Diener1
  • 1Universitätsklinik Essen
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
11. März 2003 (online)

   Lizenzen und Reprints

Zusammenfassung

Migräne ist eine der häufigsten neurologischen Erkrankungen überhaupt. In den letzten zehn Jahren konnten beachtliche Fortschritte in der Therapie erzielt werden. Durch verbesserte bildgebende Verfahren, aber auch molekularbiologische und genetische Untersuchungen konnte das Verständnis zu Ätiologie und Pathophysiologie der Migräne deutlich verbessert werden. In der Akuttherapie stehen inzwischen neben den herkömmlichen Präparaten sieben Triptane mit unterschiedlichen pharmakologischen Profilen und Darreichungsformen zur Verfügung. Auch in der Prophylaxe kann inzwischen auf ein breites Repertoire unterschiedlicher Substanzen zurückgegriffen werden, sodass in vielen Fällen eine erfolgreiche Behandlung der Erkrankung durch ein individuell zugeschnittenes Therapieregime möglich ist.

Summary

Migraine is one of the most frequently appearing neurological disorders. Within the last ten years, however, a great deal of progress could be made. Significant improvements in the field of neuroimaging, but as well through molecular and genetic studies provided new insights into etiology and pathophysiology of migraine. Aside the conventional NSAIDs, seven recently introduced triptans with different pharmacological properties and different route of administration are now available in most countries. Furthermore, for the prophylactic treatment of migraine the physician is able to use a broad spectrum of different agents, and thus is - in most of the cases - able to provide a successful custom tailored therapeutic concept.

Literatur

  • 1 Bahra A, Matharu M, Büchel C, Frakowiak RSJ. Brainstem activation specific to migraine headache.  Lancet. 2001;  357 1016-7
    CrossrefPubMedGoogle Scholar
  • 2 Behan PO, Connelly K. Prophylaxis of migraine: a comparison between naproxen sodium and pizotifen.  Headache. 1986;  26 237-239
    CrossrefPubMedGoogle Scholar
  • 3 Bellavance AJ, Meloche JP. Comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis.  Headache. 1990;  30 710-715
    CrossrefPubMedGoogle Scholar
  • 4 Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model.  Nat Med. 2002;  8 136-42
    CrossrefPubMedGoogle Scholar
  • 5 Brown EG, Endersby CA, Smith RN, Talbot JCC. The safety and tolerability of sumatriptan: an overview.  Eur Neurol. 1991;  31 339-344
    PubMedGoogle Scholar
  • 6 Buring JE, Peto R, and CH Hennekens. Low-dose aspirin for migraine prophylaxis.  JAMA. 1990;  264 1711-1713
    CrossrefPubMedGoogle Scholar
  • 7 Caekebeke JF, Ferrari MD, Zwetsloot CP, Jansen J, Saxena PR. Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks.  Neurology. 1992;  42 1522-6
    PubMedGoogle Scholar
  • 8 Cutrer FM, Sorensen AG, Weisskoff RM, Ostergaard L, Sanchez M del Rio, Lee EJ, Rosen BR, Moskowitz MA. Perfusion-weighted imaging defects during spontaneous migrainous aura.  Ann Neurol. 1998;  43 25-31
    CrossrefPubMedGoogle Scholar
  • 9 D'Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study.  Cephalalgia. 1999;  19 64-6
    CrossrefPubMedGoogle Scholar
  • 10 Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ. Efficacy, Tolerability and Safety of Oral Eletriptan and Ergotamine plus Caffeine (Cafergot((R)) in the Acute Treatment of Migraine: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Comparison.  Eur Neurol. 2002;  47 99-107
    CrossrefPubMedGoogle Scholar
  • 11 Diener C. Flunarizine for migraine prophylaxis.  In: Diener HC (Ed.) Drug treatment of migraine and other headaches.  Basel, Karger. 2000;  269-278
    PubMedGoogle Scholar
  • 12 Diener HC, for the ASASUMAMIG Study Group . Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine.  A double-blind, double-dummy, randomized, multicenter, parallel group study.  Cephalalgia. 1999;  19 581-588
    CrossrefPubMedGoogle Scholar
  • 13 Diener HC, for the RPR100893-201 Migraine Study Group. . Substance P antagonist RPR100893-201 is not effective in human migraine attacks.  6th International Headache Research Seminar, Copenhagen. 1995;  245-371
    PubMedGoogle Scholar
  • 14 Diener HC, Hartung E, Chrubasik J, Evers S, Schoenen J, Latta G, Gendolla A, on behalf of the Study Group . Acetylsalicylic acid in migraine prophylaxis: a double blind study in comparison with metoprolol.  In ¿8th Congress of the International Headache Society.  Amsterdam¿. 1997; 
    PubMedGoogle Scholar
  • 15 Diener HC, Limmroth V. Advances in the pharmacological treatment of migraine.  Exp Opinion Invest Drugs. 2001;  10 1831-1845
    PubMedGoogle Scholar
  • 16 Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells.  Neuroscience. 1991;  44 97-112
    CrossrefPubMedGoogle Scholar
  • 17 Edvinsson L, and PJ Goadsby. Neuropeptides in migraine and cluster headache.  Cephalalgia. 1994;  14 320-327
    CrossrefPubMedGoogle Scholar
  • 18 Edvinsson L, Goadsby PJ. Neuropeptides in headache.  Eur J Neurol. 1998;  5 329-41
    CrossrefPubMedGoogle Scholar
  • 19 Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.  Lancet. 2001;  358 1668-75
    CrossrefPubMedGoogle Scholar
  • 20 Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan.  Lancet. 1991;  338 13-7
    CrossrefPubMedGoogle Scholar
  • 21 Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebravascular and neuropeptide changes seen in humans and cats.  Ann Neurol. 1993;  33 48-56
    CrossrefPubMedGoogle Scholar
  • 22 Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat.  Brain. 1991;  114 1001-1011
    PubMedGoogle Scholar
  • 23 Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD. Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial.  Lancet. 2001;  358 1230-4
    CrossrefPubMedGoogle Scholar
  • 24 Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein ST, and NT Mathew. Ineffectiveness of neurokinin-1 antagonist in acute migraine: crossover study.  Cephalalgia. 1997;  17 785-790
    CrossrefPubMedGoogle Scholar
  • 25 Goldstein J, Ryan R, Jiang K, Getson A, Norman B, Block G, Lines C. the Rizatriptan Protocol 046 Study Group. . Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 and 50 mg in migraine.  Headache. 1998;  38 737-747
    CrossrefPubMedGoogle Scholar
  • 26 Gomez-Mancilla B, Cutler NR, Leibowitz MT, Spierings EL, Klapper JA, Diamond S, Goldstein J, Smith T, Couch JR, Fleishaker J, Azie N, Blunt DE. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine.  Cephalalgia. 2001;  21 727-32
    CrossrefPubMedGoogle Scholar
  • 27 Hadjikhani N, Sanchez M Del Rio, Wu O, Schwartz D, Bakker D, Fischl B, Kwong KK, Cutrer FM, Rosen BR, Tootell RB, Sorensen AG, Moskowitz MA. Mechanisms of migraine aura revealed by functional MRI in human visual cortex.  Proc Natl Acad Sci U S A. 2001;  98 4687-92
    CrossrefPubMedGoogle Scholar
  • 28 Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study.  Neurology. 1994;  44 647-651
    PubMedGoogle Scholar
  • 29 John GW, Pauwels PJ, Perez M, Halazy S, LeGrand B, Verscheure Y, Valentin JP, Palmier C, Wurch T, Chopin P, Marien M, Kleven MS, Koek W, Assie MB, Carilla-Durand E, Tarayre JP, Colpaert FCJ. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.  Pharmacol Exp Ther. 1999;  290 83-95
    PubMedGoogle Scholar
  • 30 Joutel A, Bousser M, Biousese V, Labauge P, Chabriat H, Nibbio A, Maciazek J, Meyer B, Bach M, Weissenbach J, Lathrop M G, Tournier-Lasserve E. A gene for familial hemiplegic migraine maps to chromosome 19.  Nature Genetics. 1993;  5 40-45
    CrossrefPubMedGoogle Scholar
  • 31 Kaube H, Herzog J, Kaufer T, Dichgans M, Diener HC. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine.  Neurology. 2000;  55 139-41
    CrossrefPubMedGoogle Scholar
  • 32 Klapper, J, on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group. . Divalproex sodium in migraine prophylaxis: a dose-controlled study.  Cephalalgia. 1997;  17 103-108
    CrossrefPubMedGoogle Scholar
  • 33 Lampl C, Buzath A, Klinger D, Neumann K. Lamotrigine in the prophylactic treatment of migraine aura - a pilot study.  Cephalalgia. 1999;  19 58-63
    CrossrefPubMedGoogle Scholar
  • 34 Limmroth V, May A, Auerbach P, Wosnitza G, Eppe T, Diener HC. Changes of cerebral blood flow velocity after treatment with sumatriptan or placebo and its implication in the pathophysiology of migraine.  J Neurol Sci. 1996;  138 60-65
    CrossrefPubMedGoogle Scholar
  • 35 Limmroth V, Katsarava Z, Diener HC. Acetylsalicylic acid in the treatment of migraine and other headache - a historical and current overview.  Cephalalgia. 1999;  19 545-551
    CrossrefPubMedGoogle Scholar
  • 36 Limmroth V, May A, Diener HC. Lysine-acetylsalicylic acid in acute migraine attacks.  Eur Neurol. 1999;  41 88-93
    CrossrefPubMedGoogle Scholar
  • 37 Limmroth V, Michel MC. The Prevention of Migraine: a critical review with special emphasis on ß-blockers.  Br J Clin Pharmacol. 2001;  52 237-243
    CrossrefPubMedGoogle Scholar
  • 38 Limmroth V, Katsarava Z, Liedert B, Schubert K, Michel M, Diener HC. A new invivo rat model for CGRP release following the activation of the trigeminal vascular system.  Pain. 2001;  92 101-106
    CrossrefPubMedGoogle Scholar
  • 39 Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, Stacey B, Tepper S. Efficacy of gabapentin in migraine prophylaxis.  Headache. 2001;  4 119-28
    PubMedGoogle Scholar
  • 40 Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL. Migraine prophylaxis with divalproex.  Arch Neurol. 1995;  52 281-286
    PubMedGoogle Scholar
  • 41 May A, Gijsman HJ, Wallnöfer A, Jones R, Diener HC, Ferrari MD. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks.  Pain. 1996;  67 375-378
    CrossrefPubMedGoogle Scholar
  • 42 May A, Kaube H, Buchel C, Eichten C, Rijntjes M, Juptner M, Weiller C, Diener HC. Experimental cranial pain elicited by capsaicin: a PET study.  Pain. 1998;  74 61-6
    CrossrefPubMedGoogle Scholar
  • 43 Melchart D, Linde K, Fischer P, White A, Allais G, Vickers A, Berman B. Acupuncture for recurrent headaches: a systematic review of randomized controlled trials.  Cephalalgia. 1999;  19 779-786
    CrossrefPubMedGoogle Scholar
  • 44 Moskowitz MA. Basic mechanisms in vascular headache.  Neurologic Clinics. 1990;  8 801-815
    PubMedGoogle Scholar
  • 45 Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.  TiPS. 1992;  13 307-311
    CrossrefPubMedGoogle Scholar
  • 46 Myllyla VV, Havanka H, Herrala L, Kangasniemi P, Rautakorpi I, Turkka J, Vapaatalo H, Eskerod O. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: Comparable effect in a double-blind, randomized, controlled, parallel-group study.  Headache. 1998;  38 201-207
    CrossrefPubMedGoogle Scholar
  • 47 Ophoff RA, Terwindt GM, Vergouwe MN, van R Eijk, Oefner PJ, Hoffman SMG, Lamerdin JE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van GB Ommen, Hofker MH, Ferrari MD, Frants RR. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4.  Cell. 1997;  87 543-552
    PubMedGoogle Scholar
  • 48 Roon I K, Olesen J, Diener HC, Ellis P, Hettiarachchi J, Poole PH, Christianssen I, Kleinermans D, Kok JG, Ferrari MD. No acute antimigraine efficiacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials.  Ann Neurol. 2000;  47 238-241
    CrossrefPubMedGoogle Scholar
  • 49 Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura.  Cephalalgia. 1997;  17 109-12
    CrossrefPubMedGoogle Scholar
  • 50 Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study.  Headache. 2001;  41 968-75
    CrossrefPubMedGoogle Scholar
  • 51 Tfelt-Hansen P, Henry P, Mulder LJ, Schaeldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine.  Lancet. 1995;  346 923-926
    CrossrefPubMedGoogle Scholar
  • 52 Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W, Block GA, Reines SA, Visser WH. the Rizatriptan 030 Study Group . Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine.  Headache. 1998;  38 748-755
    CrossrefPubMedGoogle Scholar
  • 53 The Diclofenac-K/Sumatriptan Migraine Study Group . Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal antiinflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo.  Cephalalgia. 1999;  19 232-240
    CrossrefPubMedGoogle Scholar
  • 54 Weiller C, May A, Limmroth V, Jüptner M, Kaube H, van Schayck R, Coenen HH, Diener HC. Brain stem activation in spontaneous human migraine attacks. Nature.  Medicine. 1995;  1 658-660
    CrossrefPubMedGoogle Scholar

Anschrift des Verfassers

PD Dr. Volker Limmroth

Leitender Oberarzt

Neurologische

Universitätsklinik Essen

Hufelandstr. 55

45122 Essen

      >